| 000 | 01288 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250516060038.0 | ||
| 264 | 0 | _c20120717 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1435-4373 | ||
| 024 | 7 |
_a10.1007/s10096-011-1430-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAndrès, E | |
| 245 | 0 | 0 |
_aCationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology _cJun 2012 |
||
| 300 |
_a881-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-Infective Agents _xpharmacology |
| 650 | 0 | 4 |
_aAntimicrobial Cationic Peptides _xpharmacology |
| 650 | 0 | 4 |
_aBacterial Infections _xdrug therapy |
| 650 | 0 | 4 |
_aBiomedical Research _xtrends |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMycoses _xdrug therapy |
| 650 | 0 | 4 |
_aPolycyclic Compounds _xpharmacology |
| 773 | 0 |
_tEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology _gvol. 31 _gno. 6 _gp. 881-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10096-011-1430-8 _zAvailable from publisher's website |
| 999 |
_c21200997 _d21200997 |
||